PRESS RELEASES

Spruce Biosciences Achieves Proof of Concept in Phase 2 Study of Tildacerfont in Congenital Adrenal Hyperplasia

– Tildacerfont demonstrates meaningful reduction in key disease biomarkers adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17-OHP) and androstenedione (A4)
– Well-tolerated and safe, tildacerfont holds potential as a treatment for patients with congenital adrenal hyperplasia, a rare endocrine disorder

Read More +

 

Spruce Biosciences Announces Presentation of Positive Topline Data from Phase 2 Study of Tildacerfont (SPR001) in Congenital Adrenal Hyperplasia at the 2019 Annual Meeting of the Endocrine Society (ENDO)

Tildacerfont demonstrates potential to become the first approved therapy for congenital adrenal hyperplasia, a rare endocrine disorder

Read More +

 


 

IN THE NEWS

Neurocrine Shines In Congenital Adrenal Hyperplasia, But Competitor Is Close

Spruce’s competing drug with same mechanism of action is also in Phase II, with data expected at the end of March.

Read More +

 

Start-Up Spruce Repurposes Lilly Drug For Genetic Adrenal Condition

Emerging Company Profile: Spruce and Neurocrine are both testing CRF-R1 antagonists for the orphan disease congenital adrenal hyperplasia, with Phase II data coming soon.

Read More +

ALL NEWS

Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. We are leveraging our extensive expertise in endocrinology and orphan drug development to meet the significant unmet need of patients suffering from these diseases. We are committed to transforming the quality of life for patients who have been underserved by scientific innovation.